C4 Therapeutics, a biotech developing small molecules designed to take advantage of a cellular mechanism as a way to treat disease, has raised $170 million in venture equity and debt to start human testing.

The Watertown, MA-based firm is among a number of companies competing in the popular protein degradation space, in which drug developers aim to leverage cells’ existing recycling apparatus to destroy disease-causing proteins rather than target them for inhibition.

C4T, names after the common plastic explosive C-4, launched in 2016 with $73 million from financial backers including Cobro Ventures, an investment firm launched by tech entrepreneur Marc… Read more »